4.6 Article

The Initiative to Maximize Progress in Adolescent and Young Adult Cancer Therapy (IMPACT) Cohort Study: a population-based cohort of young Canadians with cancer

Journal

BMC CANCER
Volume 14, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1471-2407-14-805

Keywords

Adolescents; Young adults; Cancer; Treatment; Recurrence; Survival; Cohort; Population-based

Categories

Funding

  1. Childhood Cancer Canada Foundation
  2. Kids With Cancer Society
  3. Pediatric Oncology Group of Ontario Research Unit
  4. Canadian Institutes of Health Research (CIHR) [133618]
  5. Health Services Research Chair
  6. Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC)

Ask authors/readers for more resources

Background: Cancer is the leading cause of disease-related death in adolescents and young adults (AYA). Annual improvements in AYA cancer survival have been inferior to those observed in children and older adults. Prior studies of AYA with cancer have been limited by their focus on patients from select treatment centres, reducing generalizability, or by being population-based but lacking diagnostic and treatment details. There is a critical need to conduct population-based studies that capture detailed patient, disease, treatment and system-level data on all AYA regardless of treatment location. Methods/Design: We will create a cohort of all AYA (aged 15-21 years) at the time of diagnosis with any malignancy between 1992 and 2011 in Ontario, Canada (n = 5,394). Subjects will be identified through the Ontario Cancer Registry and the final cohort will be expanded to include 2012 diagnoses, as these data become available. Detailed diagnostic, treatment and outcome data for those patients treated at a pediatric cancer centre will be provided by a population-based pediatric cancer registry (n = 1,030). For 15-18 year olds treated at adult centres (n = 923) and all 19-21 year olds (n = 3396), trained abstractors will collect the comparable data elements from medical records. We will link these data to population-based administrative health data that include physician billings, hospitalizations and emergency room visits. This will allow descriptions of health care access and use prior to cancer diagnosis, and during and after treatment. Discussion: The IMPACT cohort will serve as a platform for addressing questions that span the AYA cancer journey. These will include determining which factors influence where AYA receive care, the impact of locus of care on the types and intensity of cancer therapy, appropriateness of surveillance for disease recurrence, access to clinical trials, and receipt of palliative and survivor care. Findings using the IMPACT cohort have the potential to lead to changes in practice and cancer policy, reduce mortality, and improve quality of life for AYA with cancer. The IMPACT data platform will be a permanent resource, accessible to researchers across Canada.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Public, Environmental & Occupational Health

Childhood cancer survival and avoided deaths in Australia, 1983-2016

Danny R. Youlden, Peter D. Baade, Andrew S. Moore, Jason D. Pole, Patricia C. Valery, Joanne F. Aitken

Summary: Survival for childhood cancer in Australia has continued to improve over recent decades, with most cancers showing improvements in survival. The study also estimated the number of deaths among Australian children that were potentially avoided due to improvements in survival.

PAEDIATRIC AND PERINATAL EPIDEMIOLOGY (2023)

Article Oncology

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng

Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Substance Abuse

Publicly subsidised smoking cessation medicines in times of COVID-19 in Australia: An interrupted time series analysis

Dolly Baliunas, Coral Gartner, Samantha A. Hollingworth, Clair Sullivan, Tracy Comans, Jason D. Pole

Summary: There has been a differential change in the dispensing of subsidised smoking cessation medicines in Australia since the COVID-19 pandemic, with varenicline prescriptions largely stable and NRT patches being dispensed at a lower rate than expected.

DRUG AND ALCOHOL REVIEW (2023)

Article Oncology

The Burden of Surviving Childhood Medulloblastoma: A Population-Based, Matched Cohort Study in Ontario, Canada

Hallie Coltin, Priscila Pequeno, Ning Liu, Derek S. Tsang, Sumit Gupta, Michael D. Taylor, Eric Bouffet, Paul C. Nathan, Vijay Ramaswamy

Summary: This study characterized the late effects of childhood medulloblastoma survivors using real-world health services data. The findings reveal significant long-term medical sequelae and increased mortality rates, emphasizing the need for a re-evaluation of current treatment approaches and prioritization of interventions targeting late effects.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Hematology

Treatment patterns and outcomes in adolescents and young adults with nodular lymphocyte-predominant Hodgkin lymphoma: an IMPACT cohort study

Angela Punnett, Nancy N. N. Baxter, David Hodgson, Rinku Sutradhar, Jason D. D. Pole, Cindy Lau, Paul C. C. Nathan, Sumit Gupta

Summary: We used population-based clinical and healthcare data to study the treatment patterns and long-term outcomes of adolescents and young adults (AYA) with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). We collected detailed clinical data of AYA aged 15-21 years at diagnosis with NLPHL in Ontario, Canada between 1992 and 2012. Additional events such as subsequent malignant neoplasms, relapses, and deaths were identified through linkage to healthcare databases. The study found that AYA with NLPHL have excellent long-term survival rates, and resection alone was associated with good outcomes, but strategies to avoid chemotherapy and radiation should be considered due to the risk of subsequent malignant neoplasms.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Review Oncology

Financial toxicity among adolescent and young adult cancer survivors: A systematic review of educational attainment, employment, and income

Giancarlo Di Giuseppe, Lief Pagalan, Arif Jetha, Petros Pechlivanoglou, Jason D. Pole

Summary: The purpose of this study was to identify, evaluate, and summarize evidence on the educational attainment, employment status, and income of adolescents and young adults (AYAs) who survive cancer. A search was conducted in six databases for articles published between January 1, 2010, and March 31, 2022. Twelve articles met the inclusion criteria, which included AYA survivor population, quantitative design, and a cancer-free comparator group. The findings indicated that educational attainment was similar to that of cancer-free peers, but AYA survivors were more likely to be unemployed, have lower incomes, and require social security for income supplementation. Female gender, brain cancer diagnosis, and the presence of late-effects were identified as risk factors for severe outcomes. Limited socioeconomic evidence exists for AYAs surviving cancer, highlighting the need for further research.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2023)

Review Oncology

Outcomes of Coronavirus Disease 2019 Infection in Children and Adolescents With Cancer in Canada: Population-based Study and Systematic Review

Catherine Mark, Paul Gibson, Lucie Lafay-Cousin, Georgina Martin, Sapna Oberoi, Lucie Pecheux, Shahrad R. Rassekh, Alexandra Zorzi, Sarah Alexander, Sumit Gupta

Summary: This retrospective study investigated the outcomes of 86 children with cancer who were diagnosed with COVID-19. 41.9% of the patients required hospitalization, but only 11.6% of hospitalizations were attributed to the virus. There were no deaths directly caused by COVID-19, and the findings support minimizing the interruption of chemotherapy after infection.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2023)

Review Gastroenterology & Hepatology

Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review

Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Y. X. Yu, Jill Tinmouth, Nancy N. Baxter

Summary: A scoping review found limited research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy. There was significant variation in the characteristics and results of the included studies across different countries. Future research should focus on underinvestigated interventions and develop consensus-based guidelines for study design.

BMJ OPEN GASTROENTEROLOGY (2023)

Review Health Care Sciences & Services

Facilitators and barriers to implementing electronic patient-reported outcome and experience measures in a health care setting: a systematic review

Ben G. Glenwright, Joshua Simmich, Michelle Cottrell, Shaun P. O'Leary, Clair Sullivan, Jason D. Pole, Trevor Russell

Summary: This systematic literature review identifies factors influencing the implementation of ePROMs and ePREMs in healthcare settings. Results indicate that 96 code categories influence the implementation of ePROMs and ePREMs, providing an implementation checklist for clinicians, organizations, and policymakers.

JOURNAL OF PATIENT-REPORTED OUTCOMES (2023)

Article Oncology

Rates and predictors of visits to primary care physicians during and after treatment of childhood acute lymphoblastic leukemia: A population-based cohort study

Vicky R. Breakey, Rinku Sutradhar, Paul C. Nathan, Serina Patel, Laura Wheaton, Qing Li, Mylene Bassal, Paul Gibson, Jason D. Pole, Uma Athale, Sumit Gupta

Summary: Patient re-engagement with primary care physicians (PCPs) during and after treatment for acute lymphoblastic leukemia (ALL) is low. Involvement of PCPs during treatment can improve post-treatment engagement with PCPs among ALL survivors.

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

A qualitative exploration of parental caregivers' experience caring for children who have survived medulloblastoma

Priya Sayal, Sara Rizakos, Emily Lam, Julie Constantin, Catherine Diskin, Ute Bartels, Julia Orkin, Paul C. Nathan

Summary: This study aimed to explore the experience of parental caregivers caring for medulloblastoma survivors. The study found that parental caregivers face long-term challenges and personal and family impacts. The conclusion of this study is that further improvement is needed in care models and support systems for families with a child who has survived medulloblastoma.

PEDIATRIC BLOOD & CANCER (2023)

Editorial Material Oncology

Prevention of treatment abandonment in sub-Saharan Africa; Lessons learned in Malawi that guide the way forward to cost-effective interventions: A report from CANCaRe Africa

Junious Sichali, Avi Denburg, Harriet Khofi, Cecilia Mdoka, Deborah Nyirenda, Yamikani Chimalizeni, George Chagaluka, Elizabeth Molyneux, Marc Y. R. Henrion, Sumit Gupta, Trijn Israels

PEDIATRIC BLOOD & CANCER (2023)

Article Pediatrics

Inter-Rater Reliability, Construct Validity, and Feasibility of the Modified Which Health Approaches and Treatments Are You Using? (WHAT) Questionnaires for Assessing the Use of Complementary Health Approaches in Pediatric Oncology

Mohammad R. Alqudimat, Karine Toupin April, Lindsay Jibb, Charles Victor, Paul C. Nathan, Jennifer Stinson

Summary: This study aimed to test the inter-rater reliability, construct validity, and feasibility of the modified Which Health Approaches and Treatments Are You Using? (WHAT) questionnaires in pediatric oncology. The results showed strong inter-rater reliability and strong agreements between the modified WHAT and the diary. Significant relationships were found between recent and non-recent CHA users in relation to the easy access to CHA. The feasibility of the modified WHAT was also demonstrated.

CHILDREN-BASEL (2023)

Article Oncology

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study

Colin Sue-Chue-Lam, Christine Brezden-Masley, Rinku Sutradhar, Amy Y. X. Yu, Nancy N. Baxter

Summary: This study examined the association between the duration of oxaliplatin-containing adjuvant chemotherapy and mortality in stage III colon cancer. The results showed that compared to receiving a full course of treatment, patients who received only 50% of the course had slightly higher overall mortality and cancer-specific mortality, but the differences were not significant.

CURRENT ONCOLOGY (2023)

No Data Available